OXYCYTE

OXYCYTE is the company’s perfluorocarbon (PFC) therapeutic oxygen carrier. It is designed to enhance oxygen delivery to damaged tissues. When used as an intravenous emulsion, OXYCYTE can carry many times more oxygen than hemoglobin, making it an effective means of transporting oxygen to tissues and carrying carbon dioxide to the lungs for disposal.  OXYCYTE is not a blood substitute.  Because it is a PFC, and not based on hemoglobin, it does not have the safety issues associated with hemoglobin-based products. In fact, we believe that OXYCYTE has a very favorable risk-benefit profile for its potential indications.

The chart below summarizes the advantages of OXYCYTE.

PFC Advantages	Hemoglobin
Superior safety profile	Reported safety issues
No supply issues	Outdated human blood/limited supply
No animal hemoglobin	Cow's blood
No disease transmission/typing, cross matching	Potential for disease transmission/antibody formation

On August 13, 2009, the company received approval from Swissmedic to conduct a Phase II, dose escalation, clinical trial in Switzerland using OXYCYTE in traumatic brain injury.

The company believes OXYCYTE has the potential for use in multiple indications, including traumatic brain injury, sickle cell crisis, trauma, wound care, decompression sickness, acute respiratory distress syndrome, stroke, myocardial infarction, surgery, diabetic wounds and ulcers and cosmetic applications.

Dr. Bruce D. Spiess, MD, a member of the company’s board of directors and co-chair of the company’’s Medical Advisory Board discusses how OXYCYTE works in the body in these videos.